AustralianSuper Pty Ltd Makes New $1.02 Million Investment in IQVIA Holdings Inc. $IQV

AustralianSuper Pty Ltd bought a new position in IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 4,512 shares of the medical research company’s stock, valued at approximately $1,017,000.

Other hedge funds have also added to or reduced their stakes in the company. Ameliora Wealth Management Ltd. bought a new stake in IQVIA in the fourth quarter worth approximately $25,000. International Assets Investment Management LLC bought a new stake in IQVIA in the fourth quarter worth approximately $27,000. Activest Wealth Management increased its holdings in IQVIA by 590.0% in the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after purchasing an additional 118 shares in the last quarter. Physician Wealth Advisors Inc. increased its holdings in IQVIA by 1,340.0% in the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after purchasing an additional 134 shares in the last quarter. Finally, Westside Investment Management Inc. increased its holdings in IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after purchasing an additional 101 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently commented on IQV. Royal Bank Of Canada began coverage on IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price objective for the company. TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and boosted their price objective for the company from $174.00 to $213.00 in a report on Monday, March 9th. Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective for the company in a report on Friday, March 6th. Weiss Ratings downgraded IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Finally, UBS Group decreased their price objective on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a report on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, IQVIA currently has a consensus rating of “Buy” and a consensus target price of $225.69.

IQVIA Stock Down 0.7%

Shares of NYSE:IQV opened at $169.56 on Friday. The stock has a market cap of $28.30 billion, a price-to-earnings ratio of 21.01, a PEG ratio of 1.63 and a beta of 1.18. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The business’s 50 day moving average is $170.14 and its 200 day moving average is $199.19.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.83 by $0.07. The company had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.IQVIA’s quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has initiated a stock buyback plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.